Future therapies for the prevention and treatment of venous and arterial thrombosis

Abstract

The incidence of thrombosis as a complication of invasive surgery, in cancer patients, as a cause or complication of stroke, acute myocardial infarction (AMI), thrombolysis, unstable angina (UA) or angioplasty is substantial. To better serve this patient population in the prevention and prophylaxis of thrombosis, new types of anticoagulant drugs are under development by the pharmaceutical industry. The goal of these efforts are orally-active anticoagulants with specificity and pharmacokinetic properties that could translate into better control of anticoagulation and thrombosis and less bleading liability compared to the currently used anticoagulants: heparin, the low molecular weight heparins and warfarin. Various approaches for which there is a great deal of activity include: tissue factor/Factor VIIa inhibitors, Factor Xa inhibitors, thrombin inhibitors, glycoprotein IIb/IIIa antagonists. There is also interest in Factor IXa inhibitors, thrombin receptor antagonists and inhibitors of plasminogen activator inhibitor-1.

• anticoagulant
• antidote
• antithombotic
• bleeding risk
• Factor IXa
• Factor Xa
• glycoprotein IIb/IIIa
• heparin
• low molecular weight heparin
• plasminogen activator inhibitor
• pharmacodynamics
• pharmacokinetics
• thrombin
• thrombin receptor
• thrombosis
• tissue factor/Factor VIIa